DDInter927 DDInter342
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stavudine
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Abatacept
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Tildrakizumab
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Stavudine
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Certolizumab pegol may lead to a major life threatening interaction when taken with Abatacept
Certolizumab pegol may lead to a major life threatening interaction when taken with Tildrakizumab